If You're Betting on Acquisitions, Bet Private
This article was originally published in Start Up
Executive Summary
It's an odd biotech fact: given the choice within a group of more or less similarly sized and staged biotechs, drug firms generally prefer to acquire the private ones. We look at acquisitions of public and private biotechs since 2001 and explain several reasons for the phenomenon.